Stem definition | Drug id | CAS RN |
---|---|---|
bronchodilators, phenethylamine derivatives | 1575 | 34391-04-3 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 180 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 46 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 2.23 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
March 25, 1999 | FDA | OAK PHARMS INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Asthma | 211.75 | 13.86 | 195 | 14143 | 91347 | 46580377 |
Chronic obstructive pulmonary disease | 145.36 | 13.86 | 129 | 14209 | 57504 | 46614220 |
Infective pulmonary exacerbation of cystic fibrosis | 117.11 | 13.86 | 60 | 14278 | 10747 | 46660977 |
Dyspnoea | 71.73 | 13.86 | 330 | 14008 | 515218 | 46156506 |
Pneumonia | 67.93 | 13.86 | 261 | 14077 | 376059 | 46295665 |
Sinusitis | 61.48 | 13.86 | 128 | 14210 | 129640 | 46542084 |
Wheezing | 57.08 | 13.86 | 76 | 14262 | 53310 | 46618414 |
Bronchitis | 54.29 | 13.86 | 108 | 14230 | 105871 | 46565853 |
Cystic fibrosis | 50.44 | 13.86 | 24 | 14314 | 3664 | 46668060 |
Product quality issue | 44.80 | 13.86 | 55 | 14283 | 35593 | 46636131 |
Cough | 42.47 | 13.86 | 161 | 14177 | 230088 | 46441636 |
Rheumatoid arthritis | 40.11 | 13.86 | 12 | 14326 | 240203 | 46431521 |
Chest discomfort | 38.07 | 13.86 | 85 | 14253 | 90184 | 46581540 |
Anaphylactic reaction | 30.69 | 13.86 | 57 | 14281 | 53055 | 46618669 |
Infusion site erythema | 29.60 | 13.86 | 22 | 14316 | 7620 | 46664104 |
Toxicity to various agents | 28.12 | 13.86 | 15 | 14323 | 211751 | 46459973 |
Respiratory failure | 28.06 | 13.86 | 78 | 14260 | 94738 | 46576986 |
Productive cough | 25.11 | 13.86 | 51 | 14287 | 50664 | 46621060 |
Chest pain | 23.66 | 13.86 | 112 | 14226 | 176212 | 46495512 |
Acute respiratory failure | 23.09 | 13.86 | 36 | 14302 | 29102 | 46642622 |
Nasal congestion | 22.20 | 13.86 | 47 | 14291 | 48066 | 46623658 |
Pulmonary function test decreased | 21.89 | 13.86 | 14 | 14324 | 3806 | 46667918 |
Haemoptysis | 21.65 | 13.86 | 33 | 14305 | 26156 | 46645568 |
Drug ineffective | 20.71 | 13.86 | 123 | 14215 | 677715 | 45994009 |
Upper respiratory tract infection | 20.51 | 13.86 | 54 | 14284 | 63502 | 46608222 |
Administration site swelling | 20.39 | 13.86 | 9 | 14329 | 1156 | 46670568 |
Headache | 20.25 | 13.86 | 230 | 14108 | 478122 | 46193602 |
Cardiac failure congestive | 20.14 | 13.86 | 68 | 14270 | 91682 | 46580042 |
Anxiety | 19.81 | 13.86 | 109 | 14229 | 181848 | 46489876 |
Pseudomonas infection | 19.10 | 13.86 | 19 | 14319 | 9739 | 46661985 |
Respiratory distress | 18.11 | 13.86 | 34 | 14304 | 31882 | 46639842 |
Bronchospasm | 17.76 | 13.86 | 23 | 14315 | 15684 | 46656040 |
Maternal exposure during pregnancy | 17.32 | 13.86 | 5 | 14333 | 102544 | 46569180 |
Drug intolerance | 17.30 | 13.86 | 12 | 14326 | 147037 | 46524687 |
Infusion site swelling | 16.87 | 13.86 | 14 | 14324 | 5685 | 46666039 |
Treatment failure | 16.74 | 13.86 | 4 | 14334 | 93083 | 46578641 |
Hyperacusis | 16.37 | 13.86 | 9 | 14329 | 1855 | 46669869 |
Heart rate increased | 16.03 | 13.86 | 55 | 14283 | 74736 | 46596988 |
Dysphonia | 15.98 | 13.86 | 36 | 14302 | 38378 | 46633346 |
Poor quality device used | 15.32 | 13.86 | 9 | 14329 | 2103 | 46669621 |
Bronchospasm paradoxical | 15.28 | 13.86 | 4 | 14334 | 102 | 46671622 |
Enterovirus infection | 14.95 | 13.86 | 6 | 14332 | 608 | 46671116 |
Respiratory tract infection | 14.66 | 13.86 | 30 | 14308 | 29942 | 46641782 |
Rhinitis allergic | 14.54 | 13.86 | 14 | 14324 | 6894 | 46664830 |
Bronchitis chronic | 13.95 | 13.86 | 11 | 14327 | 4156 | 46667568 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Asthma | 95.86 | 16.96 | 69 | 5761 | 36105 | 29910543 |
Infective pulmonary exacerbation of cystic fibrosis | 92.07 | 16.96 | 41 | 5789 | 8531 | 29938117 |
Chronic obstructive pulmonary disease | 72.92 | 16.96 | 65 | 5765 | 46061 | 29900587 |
Dyspnoea | 55.73 | 16.96 | 166 | 5664 | 333129 | 29613519 |
Respiratory distress | 37.88 | 16.96 | 39 | 5791 | 32933 | 29913715 |
Cough | 37.17 | 16.96 | 78 | 5752 | 125564 | 29821084 |
Pneumonia | 36.81 | 16.96 | 145 | 5685 | 334161 | 29612487 |
Upper respiratory tract infection | 30.66 | 16.96 | 32 | 5798 | 27444 | 29919204 |
Bronchospasm paradoxical | 29.90 | 16.96 | 6 | 5824 | 72 | 29946576 |
Toxic optic neuropathy | 29.09 | 16.96 | 9 | 5821 | 673 | 29945975 |
Status asthmaticus | 26.01 | 16.96 | 7 | 5823 | 318 | 29946330 |
Respiratory failure | 22.53 | 16.96 | 56 | 5774 | 100586 | 29846062 |
Sinusitis | 20.95 | 16.96 | 29 | 5801 | 33316 | 29913332 |
Cystic fibrosis | 18.56 | 16.96 | 9 | 5821 | 2265 | 29944383 |
Oxygen saturation decreased | 17.77 | 16.96 | 31 | 5799 | 43409 | 29903239 |
Product quality issue | 17.67 | 16.96 | 20 | 5810 | 18754 | 29927894 |
Source | Code | Description |
---|---|---|
FDA MoA | N0000009922 | Adrenergic beta2-Agonists |
FDA EPC | N0000175779 | beta2-Adrenergic Agonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Bronchospasm | indication | 4386001 | |
Acute exacerbation of asthma | indication | 708038006 | |
Bronchospasm Prevention | indication | ||
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Hypokalemia | contraindication | 43339004 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Ketoacidosis | contraindication | 56051008 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Prolonged QT interval | contraindication | 111975006 | |
Seizure disorder | contraindication | 128613002 | |
Chronic myocardial ischemia | contraindication | 413844008 | DOID:3393 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.07 | acidic |
pKa2 | 9.46 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-2 adrenergic receptor | GPCR | AGONIST | Ki | 5.42 | CHEMBL | CHEMBL |
ID | Source |
---|---|
D02281 | KEGG_DRUG |
50293-90-8 | SECONDARY_CAS_RN |
4021157 | VANDF |
C0772501 | UMLSCUI |
CHEBI:8746 | CHEBI |
68H | PDB_CHEM_ID |
123600 | PUBCHEM_CID |
CHEMBL1002 | ChEMBL_ID |
CHEMBL1201061 | ChEMBL_ID |
CHEMBL3989693 | ChEMBL_ID |
DB13139 | DRUGBANK_ID |
D064412 | MESH_DESCRIPTOR_UI |
9816 | IUPHAR_LIGAND_ID |
7681 | INN_ID |
EDN2NBH5SS | UNII |
237159 | RXNORM |
14178 | MMSL |
167701 | MMSL |
20402 | MMSL |
8043 | MMSL |
d04427 | MMSL |
007763 | NDDF |
007764 | NDDF |
010710 | NDDF |
116090007 | SNOMEDCT_US |
398965008 | SNOMEDCT_US |
412236007 | SNOMEDCT_US |
426604008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Levalbuterol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-4145 | SOLUTION | 0.31 mg | RESPIRATORY (INHALATION) | ANDA | 27 sections |
Levalbuterol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-4146 | SOLUTION | 0.63 mg | RESPIRATORY (INHALATION) | ANDA | 27 sections |
Levalbuterol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-4147 | SOLUTION, CONCENTRATE | 1.25 mg | RESPIRATORY (INHALATION) | ANDA | 26 sections |
Levalbuterol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-4148 | SOLUTION | 1.25 mg | RESPIRATORY (INHALATION) | ANDA | 27 sections |
Levalbuterol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-9930 | SOLUTION | 0.31 mg | RESPIRATORY (INHALATION) | ANDA | 31 sections |
Levalbuterol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-9931 | SOLUTION | 0.63 mg | RESPIRATORY (INHALATION) | ANDA | 31 sections |
Levalbuterol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-9932 | SOLUTION | 1.25 mg | RESPIRATORY (INHALATION) | ANDA | 31 sections |
Levalbuterol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6993 | SOLUTION, CONCENTRATE | 1.25 mg | RESPIRATORY (INHALATION) | ANDA | 27 sections |
Levalbuterol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-9690 | SOLUTION | 0.31 mg | RESPIRATORY (INHALATION) | ANDA | 28 sections |
Levalbuterol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-9691 | SOLUTION | 0.63 mg | RESPIRATORY (INHALATION) | ANDA | 28 sections |
Levalbuterol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-9692 | SOLUTION | 1.25 mg | RESPIRATORY (INHALATION) | ANDA | 28 sections |
Levalbuterol tartrate HFA inhalation | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2927 | AEROSOL, METERED | 45 ug | ORAL | NDA AUTHORIZED GENERIC | 27 sections |
Levalbuterol Inhalation Solution | Human Prescription Drug Label | 1 | 16714-094 | SOLUTION | 0.31 mg | RESPIRATORY (INHALATION) | ANDA | 27 sections |
Levalbuterol Inhalation Solution | Human Prescription Drug Label | 1 | 16714-095 | SOLUTION | 0.63 mg | RESPIRATORY (INHALATION) | ANDA | 27 sections |
Levalbuterol Inhalation Solution | Human Prescription Drug Label | 1 | 16714-096 | SOLUTION | 1.25 mg | RESPIRATORY (INHALATION) | ANDA | 27 sections |
Xopenex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-171 | SOLUTION, CONCENTRATE | 1.25 mg | RESPIRATORY (INHALATION) | NDA | 27 sections |
Xopenex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-172 | SOLUTION | 0.31 mg | RESPIRATORY (INHALATION) | NDA | 27 sections |
Xopenex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-173 | SOLUTION | 0.63 mg | RESPIRATORY (INHALATION) | NDA | 27 sections |
Xopenex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-174 | SOLUTION | 1.25 mg | RESPIRATORY (INHALATION) | NDA | 27 sections |
Xopenex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-153 | SOLUTION | 1.25 mg | RESPIRATORY (INHALATION) | NDA | 24 sections |
Levalbuterol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35573-443 | SOLUTION | 0.31 mg | RESPIRATORY (INHALATION) | ANDA | 18 sections |
Levalbuterol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35573-444 | SOLUTION | 0.63 mg | RESPIRATORY (INHALATION) | ANDA | 18 sections |
Levalbuterol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35573-445 | SOLUTION | 1.25 mg | RESPIRATORY (INHALATION) | ANDA | 18 sections |
levalbuterol inhalation | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-409 | SOLUTION | 1.25 mg | RESPIRATORY (INHALATION) | ANDA | 27 sections |
levalbuterol inhalation | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-410 | SOLUTION | 0.63 mg | RESPIRATORY (INHALATION) | ANDA | 27 sections |
levalbuterol inhalation | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-412 | SOLUTION | 0.31 mg | RESPIRATORY (INHALATION) | ANDA | 27 sections |
Levalbuterol Inhalation Solution | Human Prescription Drug Label | 1 | 47335-743 | SOLUTION | 0.31 mg | RESPIRATORY (INHALATION) | ANDA | 27 sections |
Levalbuterol Inhalation Solution | Human Prescription Drug Label | 1 | 47335-746 | SOLUTION | 0.63 mg | RESPIRATORY (INHALATION) | ANDA | 27 sections |
Levalbuterol Inhalation Solution | Human Prescription Drug Label | 1 | 47335-753 | SOLUTION | 1.25 mg | RESPIRATORY (INHALATION) | ANDA | 27 sections |
Xopenex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4409 | SOLUTION | 0.63 mg | RESPIRATORY (INHALATION) | NDA | 14 sections |